Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel (MP-PDAC-01)
Sponsor: Joon Oh Park
A PHASE1/PHASE2 clinical study on Metastatic Pancreatic Cancer, this trial is ongoing. The trial is conducted by Joon Oh Park and has accumulated 9 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Recruiting → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Unknown Status → Recruiting
-
Mar 2022 — Jul 2022 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Oct 2018 — Jun 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Joon Oh Park
For direct contact, visit the study record on ClinicalTrials.gov .